Kamada Ltd. (NASDAQ:KMDA) has been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus target price of $8.50 for the company and are forecasting that the company will post ($0.04) EPS for the current quarter, according to Zacks. Zacks has also given Kamada an industry rank of 108 out of 265 based on the ratings given to its competitors.
KMDA has been the topic of a number of recent research reports. Zacks Investment Research raised Kamada from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Thursday, August 4th. TheStreet raised Kamada from a “sell” rating to a “hold” rating in a research report on Monday, September 26th. Jefferies Group reissued a “buy” rating and issued a $7.00 target price on shares of Kamada in a research report on Wednesday, August 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Kamada in a research report on Saturday, September 3rd.
Kamada (NASDAQ:KMDA) opened at 5.35 on Friday. The stock’s 50 day moving average price is $4.85 and its 200-day moving average price is $4.11. Kamada has a one year low of $3.26 and a one year high of $5.45. The firm’s market capitalization is $194.84 million.
Kamada (NASDAQ:KMDA) last announced its earnings results on Tuesday, August 2nd. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.04). Kamada had a negative return on equity of 10.59% and a negative net margin of 9.92%. The business had revenue of $19.10 million for the quarter, compared to analyst estimates of $18.50 million. On average, equities research analysts expect that Kamada will post ($0.19) EPS for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC increased its position in Kamada by 2.4% in the first quarter. Renaissance Technologies LLC now owns 170,300 shares of the company’s stock worth $652,000 after buying an additional 4,000 shares in the last quarter. Vanguard Group Inc. increased its position in Kamada by 19.0% in the second quarter. Vanguard Group Inc. now owns 327,533 shares of the company’s stock worth $1,202,000 after buying an additional 52,195 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in Kamada during the second quarter worth $1,701,000. Hedge funds and other institutional investors own 5.31% of the company’s stock.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.